ArticleFrontiers in oncology2026
Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to assess the efficacy and safety of combining transarterial chemoembolization and hepatic arterial infusion chemotherapy (TACE-HAIC) with targeted immunotherapy in patients with primary hepatocellular carcinoma (HCC) complicated by portal vein tumor thrombus (PVTT). Methods: We retrospectively analyzed clinical data from 114 patients with HCC and PVTT treated with either a quadruple-therapy group (TACE-HAIC plus targeted immunotherapy) or a triple-therapy group (TACE plus targeted immunotherapy) at the Affiliated Hospital of Xuzhou Medical University from January 2019 to September 2023. Propensity score matching was applied to these 114 patients. We compared outcomes such as overall survival (OS), progression-free survival (PFS), intrahepatic progression-free survival (IHPFS), PVTT progression-free survival (TTPFS), objective response rate (ORR), disease control rate (DCR), and the incidence of adverse events between the groups. Results: The quadruple-therapy group exhibited a markedly superior ORR of portal vein tumor thrombus relative to the triple-therapy group (P<0.05). However, no significant differences were found between the groups in OS, PFS, IHPFS, or TTPFS (P > 0.05). Conclusion: The combination of TACE-HAIC with targeted immunotherapy (the quadruple-therapy group) is an effective treatment strategy for PVTT, significantly inducing regression of intraportal tumor thrombi and achieving a higher objective response rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.